|
C2ORF69 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62470037423645E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.88178419700125E-16 |
| Normal-vs-Stage2 |
1.08529999998108E-06 |
| Normal-vs-Stage3 |
3.06159542162732E-11 |
| Normal-vs-Stage4 |
2.18047802036381E-12 |
| Stage1-vs-Stage2 |
2.887800E-01 |
| Stage1-vs-Stage3 |
4.974600E-01 |
| Stage1-vs-Stage4 |
2.624200E-02 |
| Stage2-vs-Stage3 |
2.029000E-01 |
| Stage2-vs-Stage4 |
1.421560E-02 |
| Stage3-vs-Stage4 |
1.541570E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
4.60320000006398E-07 |
| Normal-vs-Asian |
4.45779968494264E-10 |
| Caucasian-vs-AfricanAmerican |
7.708600E-01 |
| Caucasian-vs-Asian |
4.865000E-01 |
| AfricanAmerican-vs-Asian |
8.397400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.40998324127395E-14 |
| Normal-vs-Female |
1.62847513252018E-12 |
| Male-vs-Female |
1.416590E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.15993889440824E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
2.16319995249847E-09 |
| Normal-vs-Age(81-100Yrs) |
2.035800E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.322830E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.207800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.236800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.651760E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.819180E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
5.359600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.360600E-01 |
| Classical-VS-Follicular |
6.781800E-01 |
| Classical-VS-Other |
2.829800E-01 |
| Classical-VS-Normal |
1.62492241884138E-12 |
| Tall-VS-Follicular |
7.269800E-01 |
| Tall-VS-Other |
3.175200E-01 |
| Tall-VS-Normal |
5.36489999980461E-07 |
| Follicular-VS-Other |
3.370400E-01 |
| Follicular-VS-Normal |
3.60499999851882E-08 |
| Other-VS-Normal |
3.032200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.77635683940025E-14 |
| Normal-vs-N1 |
5.41788836017076E-14 |
| N0-vs-N1 |
5.356500E-02 |
|
|
